Table 1.
Pooled data of infectious complications from CAR-T cell therapy.
| Reference | CAR T-cell therapy | N | Underlying malignancy | Severity grade | Timepoint | Bacterial infection incidence (n, %) | Viral infection incidence (n, %) | Fungal infection incidence (n, %) |
|---|---|---|---|---|---|---|---|---|
| Abramson et al.34 | Lisocabtagene maraleucel | 269 | R/R B-cell lymphoma | ⩾3 | 12 months | 27/269 (10) | 4/269 (1) | 2/269 (1) |
| Locke et al.38 | Axicabtagene ciloleucel | 108 | Refractory B- cell lymphoma | All | 12 months | 44/108 (40) | 11/108 (10) | 7/108 (6) |
| Logue et al.35 | Axicabtagene ciloleucel | 85 | R/R B-cell lymphoma | All | ⩽30 days | 26/85 (31) | 12/85 (14) | 2/85 (2) |
| >30 days | 13/85 (15) | 19/85 (22) | 0/85 (0) | |||||
| Wittmann Dayagi et al.36 | CD28-based CAR T cells | 88 | R/R B-cell lymphoma | All | ⩽30 days | 22/85 (25) | 14/85 (16) | 0/85 (0) |
| 30–60 days | 8/85 (9) | 2/85 (2) | 1/85 (1) | |||||
| Baird et al.37 | Axicabtagene ciloleucel | 41 | R/R B-cell lymphoma | All | ⩽28 days | 7/41 (17.1) | 8/41 (19.5) | 4/41 (9.8) |
| >28 days | 10/41 (24.4) | 10/41 (24.4) | 9/41 (22) | |||||
| Wudhikarn et al.22 | Axicabtagene ciloleucel OR tisagenlecleucel | 60 | R/R DLBCL | All | ⩽30 days | 20/60 (33) | 10/60 (17) | 1/60 (2) |
| >30 days | 14/60 (24) | 17/60 (28) | 3/60 (5) | |||||
| Hill et al.21 | Anti-CD19 CAR autologous T cells | 133 | ALL, CLL, NHL | All | ⩽28 days | 22/133 (16.5) | 11/133 (8.3) | 4/133 (3) |
| >28 days | 7/119 (5.9) | 11/119 (9.2) | 2/119 (1.7) | |||||
| Munshi et al.41 | Idecabtagene vicleucel | 54 | R/R multiple myeloma | All | 12 months | 13/54 (24) | 15/54 (28) | 4/54 (7) |
ALL, acute lymphocytic leukaemia; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s lymphoma; R/R, relapsed/refractory.